Newsroom
Keep up with the latest
Featured
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
Media Center
Media
East Bay's Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease
July 18, 2023
San Francisco Business Times
Read Now
Press Release
East Bay's Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease
July 18, 2023
San Francisco Business Times
Read Now
Media
Sanofi taps Scribe for in vivo partnership worth more than $1.2B biobucks aimed at sickle cell and beyond
July 18, 2023
Fierce Biotech
Read Now
Press Release
Sanofi taps Scribe for in vivo partnership worth more than $1.2B biobucks aimed at sickle cell and beyond
July 18, 2023
Fierce Biotech
Read Now
Media
Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure
July 18, 2023
STAT News
Read Now
Press Release
Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure
July 18, 2023
STAT News
Read Now
Press Release
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
July 17, 2023
Read Now
Press Release
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
July 17, 2023
Read Now